Haematology 2018

RELEVANCE: CO-PRIMARY ENDPOINT INTERIM PFS BY IRC (~50% EVENTS)

1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 PFS Probability (IRC)

R-chemo (n = 517)

R 2 (n = 513)

R-chemo

Events, n (%)

119 (23)

111 (21)

77% (72%-80%) 78% (74%-82%)

3-year PFS (95% CI)

R 2

1.10 (0.85-1.43) 0.48

HR (95% CI) P value

0 6 12 18 24 30 36 42 48 54 Months from Randomization

60 66

Number of Patients at Risk

513 435 409 393 364 282 174 107 49 13 0 1 0 R 2 517 474 446 417 387 287 175 109 51 14

R-chemo

• At a median follow-up of 37.9 months, interim PFS was similar in both arms

Data cut-off31May2017. Fowleret al. RELEVANCE: Phase III Randomized Study of LenalidomidePlus Rituximab (R 2 ) Versus ChemotherapyPlus Rituximab,Followedby RituximabMaintenance,in PatientsWith Previously Untreated FollicularLymphoma. Oral presentation at:American Society of ClinicalOncology meeting.2018; Jun 1-5; Chicago,IL. Abstract 7500.